Fragile X syndrome is the most frequent cause of intellectual disability in males, affecting 1 out of 3600 boys born. For the first time, researchers at Whitehead Institute have restored activity to the fragile X syndrome gene in affected neurons using a modified CRISPR/Cas9 system they developed that removes the methylation—the molecular tags that keep the mutant gene shut off—suggesting that this method may prove to be a useful paradigm for targeting diseases caused by abnormal methylation.
Research by the lab of Whitehead Institute Founding Member Rudolf Jaenisch, which is described online this week in the journal Cell, is the first direct evidence that removing the methylation from a specific segment within the FMR1 locus can reactivate the gene and rescue fragile X syndrome neurons.
The FMR1 gene sequence includes a series of three nucleotide (CGG) repeats, and the length of these repeats determines whether or not a person will develop fragile X syndrome: A normal version of the gene contains anywhere from 5-55 CGG repeats; versions with 56-200 repeats are considered to be at a higher risk of generating some of the syndrome’s symptoms; and those versions with more than 200 repeats will produce fragile X syndrome.
Until now, the mechanism linking the excessive repeats in FMR1 to fragile X syndrome was not well understood. But Shawn Liu, a postdoctoral researcher in Jaenisch’s lab and first author of the Cellstudy, and others thought that the methylation blanketing those nucleotide repeats might play an important role in shutting down the gene’s expression.
In order to test this hypothesis, Liu removed the methylation tags from the FMR1 repeats using a CRISPR/Cas9-based technique recently developed by him and Hao Wu, a former postdoctoral researcher in the Jaenisch lab. This technique can either add or delete methylation tags from specific stretches of DNA. Removal of the tags revived the FMR1 gene’s expression to the level of the normal gene.
“These results are quite surprising—this work produced almost a full restoration of wild type expression levels of the FMR1 gene,” says Jaenisch, who is a professor of biology at Massachusetts Institute of Technology and the senior author on the study. “Often when scientists test therapeutic interventions, they only achieve partial restoration, so these results are substantial.”
The reactivated FMR1 gene rescues neurons derived from fragile X syndrome induced pluripotent stem (iPS) cells, reversing the abnormal electrical activity associated with the syndrome. When rescued neurons were engrafted into the brains of mice, the FMR1 gene remained active in the neurons for at least three months, suggesting that the corrected methylation may be sustainable in the animal.
“We showed that this disorder is reversible at the neuron level,” says Liu. “When we removed methylation of CGG repeats in the neurons derived from fragile X syndrome iPS cells, we achieved full activation of FMR1.”
The CRISPR/Cas-9-based technique may also prove useful for other diseases caused by abnormal methylation including facioscapulohumeral muscular dystrophy and imprinting diseases.
“This work validates the approach of targeting the methylation on genes, and it will be a paradigm for scientists to follow this approach for other diseases,” says Jaenisch.
The Latest on: Fragile X syndrome
Fragile-x high tea fundraiser to raise awareness and funds for genetic disorder
on July 16, 2018 at 7:30 pm
Fragile-x syndrome is the most common known cause of inherited intellectual disability and the most common cause of autism spectrum disorder. Symptoms of fragile-x are similar to autism, attention def... […]
Fragile X Symptoms May be Helped with New Pharmacological Approach
on July 16, 2018 at 5:48 am
Scientists report that a pharmacological strategy can alleviate multiple behavioral and cellular deficiencies in a mouse model of fragile X syndrome (FXS), the most common inherited form of intellectu... […]
Pharmacological Strategy Attempts To Treat Multiple Symptoms of Fragile X
on July 13, 2018 at 1:49 pm
Recent research in a mouse model of fragile X syndrome (FXS), scheduled for publication in Neuropsychopharmacology, shows that a pharmacological strategy can reduce multiple behavioral and cellular de... […]
Fragile X: New drug strategy corrects behavior/biochemical measures in mouse model
on July 13, 2018 at 2:08 am
Research in mice shows that a pharmacological strategy can alleviate multiple behavioral and cellular deficiencies in a mouse model of fragile X syndrome (FXS), the most common inherited form of intel... […]
Zynerba Pops On Positive Phase 2 Data For ZYN002 In Fragile X
on July 12, 2018 at 5:14 am
"These data are consistent and compelling, and suggest that ZYN002 may have a clinically meaningful and durable effect on the most common observable behaviors associated with childhood and adolescent ... […]
Zynerba Pharmaceuticals Announces New FAB-C Phase 2 Open-Label Data in Patients with Fragile X Syndrome
on July 12, 2018 at 4:30 am
- Presentation Today at the 16 th NFXF International Fragile X Conference - The data demonstrate that treatment with ZYN002 improved core behavioral symptoms of Fragile X syndrome with statistical sig... […]
Ovid launches mid-stage study of OV101 in Fragile X
on July 11, 2018 at 9:07 am
Ovid Therapeutics (NASDAQ:OVID) initiates a Phase 2 clinical trial, ROCKET, evaluating lead candidate OV101 in adolescent and young adult males with Fragile X syndrome. The primary endpoint of the 30- ... […]
Ovid Therapeutics Announces Initiation of Phase 2 ROCKET Clinical Trial to Evaluate OV101 in Fragile X Syndrome
on July 11, 2018 at 4:40 am
July 11, 2018 07:30 ET | Source: Ovid Therapeutics Inc. NEW YORK, July 11, 2018 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines ... […]
Fragile X syndrome caused by a "fragile" site at end of long arm of X-chromosome.
on July 10, 2018 at 11:22 pm
Fragile X syndrome is caused by a "fragile" site at the end of the long arm of the X-chromosome. It is a genetic disorder that manifests itself through a complex range of behavioural and cognitive phe... […]
Tetra Discovery Partners Initiates Phase 2 Trial of BPN14770 in Fragile X Syndrome
on July 10, 2018 at 5:00 am
GRAND RAPIDS, Mich.--(BUSINESS WIRE)--Tetra Discovery Partners today announced the initiation of a Phase 2 study of BPN14770 as a potential treatment for Fragile X Syndrome, the most common genetic fo... […]
via Google News and Bing News